Update on the Neuropsychiatry of Substance Use Disorders

被引：2
|
作者：
Kolodner, George [1 ,2 ]
Koliatsos, Vassilis E. [3 ,4 ,5 ,6 ]
机构：
[1] Kolmac Outpatient Recovery Ctr, 3919 Natl Dr, Burtonsville, MD 20910 USA
[2] Univ Maryland, Sch Med, Georgetown Univ, College Pk, MD 20742 USA
[3] Johns Hopkins Univ, Sch Med, Dept Pathol Neuropathol, Baltimore, MD USA
[4] Johns Hopkins Univ, Sch Med, Dept Neurol, Baltimore, MD 21205 USA
[5] Johns Hopkins Univ, Sch Med, Dept Psychiat & Behav Sci, Baltimore, MD 21205 USA
[6] Sheppard & Enoch Pratt Hosp, Neuropsychiat Program, Sheppard Pratt Hlth Syst, 6501 North Charles St, Baltimore, MD 21204 USA
来源：
PSYCHIATRIC CLINICS OF NORTH AMERICA | 2020年 / 43卷 / 02期
关键词：
Substance use disorders; Opioids; Cannabis; Drugs; Craving; Buprenorphine; Naltrexone; Acamprosate; RANDOMIZED CONTROLLED-TRIAL; DOUBLE-BLIND; CANNABIS; ABSTINENCE; METHADONE;
D O I：
10.1016/j.psc.2020.02.011
中图分类号：
R749 [精神病学];
学科分类号：
100205 ;
摘要：
This article reviews some of the recent discoveries about how neurobiological processes contribute to the understanding and treatment of substance use disorders. Particular focus is given to cannabis, opioids, and designer drugs. Important areas addressed include triggers and cravings, the central roles of dopamine and stress, and the endocannabinoid system. Clinical relevance of these findings for withdrawal management and relapse prevention is discussed. Also highlighted are issues related to the opioid epidemic and consequences both of continuing federal prohibition of cannabis as well as its state-by-state relaxation.
引用
收藏
页码：291 / +
页数：15
相关论文
共 50 条
  • [1] The implications of medication development in the treatment of substance use disorders in developing countries
    Thirthalli, Jagadisha
    Chand, Prabhat K.
    CURRENT OPINION IN PSYCHIATRY, 2009, 22 (03) : 274 - 280
  • [2] Substance Use Disorders in the Elderly
    Tampi, Rajesh R.
    Tampi, Deena J.
    Elson, Alisandrea
    PSYCHIATRIC CLINICS OF NORTH AMERICA, 2022, 45 (04) : 707 - 716
  • [3] Pharmacotherapy for Substance Use Disorders
    Klein, Jared Wilson
    MEDICAL CLINICS OF NORTH AMERICA, 2016, 100 (04) : 891 - +
  • [4] An Update on the Role of Common Genetic Variation Underlying Substance Use Disorders
    Johnson, Emma C.
    Chang, Yoonhoo
    Agrawal, Arpana
    CURRENT GENETIC MEDICINE REPORTS, 2020, 8 (02) : 35 - 46
  • [5] Medications for Substance Use Disorders
    Douaihy, Antoine B.
    Kelly, Thomas M.
    Sullivan, Carl
    SOCIAL WORK IN PUBLIC HEALTH, 2013, 28 (3-4) : 264 - 278
  • [6] HIV and Substance Use Disorders
    Lier, Audun J.
    Tarfa, Adati
    Shenoi, Sheela V.
    Kuo, Irene
    Springer, Sandra A.
    INFECTIOUS DISEASE CLINICS OF NORTH AMERICA, 2024, 38 (03) : 599 - 611
  • [7] Insomnia in Patients With Substance Use Disorders: Assessment and Management
    Hanacek, Cris
    Lane, Julian
    Tang, Yi-lang
    JOURNAL OF PSYCHIATRIC PRACTICE, 2025, 31 (01) : 2 - 7
  • [8] Management of Schizophrenia with Substance Use Disorders
    Lybrand, Janice
    Caroff, Stanley
    PSYCHIATRIC CLINICS OF NORTH AMERICA, 2009, 32 (04) : 821 - +
  • [9] Pharmacotherapy for Substance Use Disorders in Youths
    Hammond, Christopher J.
    Gray, Kevin M.
    JOURNAL OF CHILD & ADOLESCENT SUBSTANCE ABUSE, 2016, 25 (04) : 292 - 316
  • [10] The Classification of Substance Use Disorders: Historical, Contextual, and Conceptual Considerations
    Robinson, Sean M.
    Adinoff, Bryon
    BEHAVIORAL SCIENCES, 2016, 6 (03)
12345